Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Oil slides, yen gains as Omicron worries push investors to safe havens

11/30/2021 | 09:57am EST

NEW YORK, Nov 30 (Reuters) - Oil prices slid and global stock benchmarks fell Tuesday after a warning from drugmaker Moderna that existing vaccines are unlikely to be effective against the new coronavirus variant pushed investors into safe havens such as Treasury bonds and the yen.

"There is no world, I think, where (the effectiveness) is the same level," Moderna's chief executive Stéphane Bancel told the Financial Times in an interview.

"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to...are like 'this is not going to be good'," Bancel said.

Bancel had earlier said on CNBC that there should be more clarity on the efficacy of COVID-19 vaccines against Omicron in about two weeks, but that it could take months to begin shipping a reworked vaccine designed for the new variant.

"It's not good news, and it's coming from someone who should know," said Commonwealth Bank of Australia currency strategist Joe Capurso. "Markets have reacted in exactly the way you'd expect them to."

MSCI's gauge of stocks across the globe shed 0.39% following broad declines in Europe and Asia. Concerns that the new coronavirus variant would lead to more travel restrictions continued to hammer European travel and leisure stocks, wich are on pace for the biggest monthly fall since the initial COVID-19 lockdowns in March 2020.

In the United States, the Dow Jones Industrial Average fell 237.71 points, or 0.68%, to 34,898.23, the S&P 500 lost 30.51 points, or 0.66%, to 4,624.76 and the Nasdaq Composite dropped 57.57 points, or 0.36%, to 15,725.26.

"This whipsaw price action could become a regular feature over the next couple of weeks as information on the variant trickles out and we get a much better understanding of what we're dealing with," said Craig Erlam, senior market analyst at Oanda. "For now, markets will remain very sensitive to indications that vaccines may not protect us this winter as much as we hoped."

Omicron worries sent the yield on 10-year German Bunds - regarded as one of the safest assets in the world - to its lowest in just over a week at -0.345%.

Most other benchmark 10-year yields in the euro zone fell by a similar amount, while U.S. 10-year Treasury yields tumbled 7.5 bps to around 1.45%.

The Japanese yen - traditionally viewed as safe harbour due to its role as a funding currency - was near its highest level of the month at 112.98 yen.

Fed chairman Jerome Powell will appear before Congress later Tuesday to discuss the central bank's outlook for inflation. In prepared remarks, Powell said that "the emergence of the new Omicron variant could reduce people's willingness to work in person, which would slow progress in the labor market and intensify supply-chain disruptions."

Spot gold added 0.6% to $1,795.68 an ounce.

In the commodity markets, U.S. crude recently fell 3.75% to $67.33 per barrel and Brent was at $70.94, down 3.4% on the day.

(Reporting by David Randall; Editing by Angus MacSwan)

ę Reuters 2021
All news about MODERNA, INC.
01/14INSIDER SELL : Moderna
01/14Denver International Airport to Host COVID-19 Vaccine Booster Clinics for Employees and..
01/14Uganda to Destroy 400,000 Covid-19 Vaccines That Are Due to Expire
01/13Health Care Down Amid Valuation Concerns -- Health Care Roundup
01/13Today on Wall Street: Time for a new chapter?
01/13EUROPEAN MIDDAY BRIEFING - Stocks Down, Investors -2-
01/13WHO, EMA Warn Against Repeated COVID-19 Booster Shots
01/13New data finds AstraZeneca booster generates higher antibodies against Omicron
01/13Moderna Expects to Report Vaccine Data for Young Children in March
01/12Moderna expects COVID-19 vaccine trial data for children aged 2-5 in March
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 480 M - -
Net income 2021 11 079 M - -
Net cash 2021 9 706 M - -
P/E ratio 2021 7,75x
Yield 2021 -
Capitalization 83 008 M 83 008 M -
EV / Sales 2021 4,19x
EV / Sales 2022 2,97x
Nbr of Employees 1 300
Free-Float -
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 19
Last Close Price 204,73 $
Average target price 273,06 $
Spread / Average Target 33,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
CELLTRION, INC.-13.64%20 026